Clinical Report: Aptamer Tests Face the Validation Challenge
Background
Aptamers are short, single-stranded DNA or RNA molecules that can bind specific targets, making them valuable in diagnostics. Their development through systematic evolution of ligands by exponential enrichment (SELEX) has been a key method, but traditional SELEX can be labor-intensive and may yield aptamers that perform poorly in complex clinical samples. Newer selection methods, such as microfluidic platforms and nuclease-assisted techniques, are being explored to enhance their clinical applicability.
Data Highlights
No numerical data available in the source material.
Key Findings
- Aptamers can recognize a wide range of targets, including proteins and whole cells.
- New selection methods, such as microfluidic platforms and nuclease-assisted techniques, aim to improve aptamer performance.
- AI and machine learning are being utilized to predict aptamer structures and analyze large datasets.
- Clinical validation of aptamers requires rigorous testing for analytical sensitivity, specificity, and reproducibility.
- Despite thousands of aptamers developed, few have achieved routine clinical use.
Clinical Implications
Clinical laboratories must ensure that aptamer-based tests demonstrate analytical performance and provide useful information beyond existing methods.
Conclusion
Aptamers present opportunities in diagnostics, but challenges in validation and clinical application must be addressed.
Related Resources & Content
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics, Signal Transduction and Targeted Therapy, 2026 -- Review on aptamer development and validation challenges
- Sequential Testing Approach As an Efficient and Easier Alternative for the Validation of New Predictive Technologies in the Clinic, J Clin Oncol, 2009 -- Study on validation approaches
- Companion testing using next-generation sequencing as compared with FDA-cleared kits, ASCO Publications, 2016 -- Comparison of testing methods
- A novel aptamer-based non-invasive test for lung cancer: A proof-of-concept, ASCO Publications, 2025 -- Proof-of-concept study for lung cancer diagnostics
- ASCO Publications — Technical validation of a high-sensitivity target capture NGS assay using unique molecular identifier approach.
- Laboratory Developed Tests | FDA
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics | Signal Transduction and Targeted Therapy
- JCI Insight - A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes
Based on findings from:
Aptamer Tests Face the Validation Challenge
The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/october/aptamer-tests-face-the-validation-challenge/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
